Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.

Abstract: The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.

Abstract: The invention therefore relates to compounds of the formula I in which the variables are as defined in the specification, to pharmaceutical compositions containing them and to their use for therapeutically lowering blood glucose levels.

Abstract: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diones, pharmaceutically acceptable salts thereof and physiologically functional derivatives. The invention therefore relates to compounds of the formula I, in which the radicals have the given meanings, and to their physiologically tolerated salts and processes for preparing them. The compounds are suitable for use as antidiabetics, for example.

Abstract: The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them consisting of the structure of formula I: Wherein R1, R2, A, B, D and E are defined herein. These 4-benzimidazol-2-ylpyridazin-3-ones and their derivatives and compositions comprising them are useful in the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase-3 ? (GSK-3?) which is believed to cause the neurodegeneration that results in these diseases.

Abstract: The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments.

Abstract: The present invention relates to pyridazinone compounds and their derivatives according to the general formula (I), with the substituents X, R1 and R2 defined herein, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3? (glycogen synthase kinase-3?) which are useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovary syndrome and syndrome X or immunodeficiency.

Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.

Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Abstract: A platform for industrial installations, in particular for high-pressure descalers (3a) or other machines (3) with optionally bundled supply, discharge, and/or distribution conduits (11) which in operational position, are connectable with fixed conduits of a respective machine (3), can be provided as a central installation for connecting media and power lines that can be monitored and easily inspected, with an arrangement being carried out in an immediate proximity with predetermined distance, lateral position and height with regard to a connectable machine (3) with control units (4), devices (4), drives (5) and drive consoles (5a), distribution blocks (6), valve units (7), control elements and the like being distributed over a horizontal, polygonal platform foundation surface (2) according to their functions with regard to the machine (3).

Abstract: The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade.

Abstract: Disclosed are compounds of the general formula (I), with the definitions of the substituents R1 to R5, A and X being detailed in the text, and to their physiologically tolerated salts, to processes for preparing these compounds and to the use thereof as inhibitors of hormone-sensitive lipase (HSL).

Abstract: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diones, pharmaceutically acceptable salts thereof and physiologically functional derivatives. The invention therefore relates to compounds of the formula I, in which the radicals have the given meanings, and to their physiologically tolerated salts and processes for preparing them. The compounds are suitable for use as antidiabetics, for example.

Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.

Abstract: A system for medical detection and treatment comprising a number of treatment and/or detection devices which exchange data with each other within the context of a medical treatment, in particular a surgical or radiotherapeutic and/or radiosurgical operation, wherein the data are exchanged via radio interfaces in and/or on the devices.

Abstract: The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are independently 0, 1, 2, or 3, provided that n+p is a least 1; and unsubstituted and at least monosubstituted C1-C10-alkylene-Y, C2-C10-alkylene-Y, C3-C10-cycloalkylene-Y and C3-C10-cycloalkenylene-Y; and R1, A, B, Q, T, Y, E and W have the meanings given in the description. These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance, type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.

Abstract: The invention therefore relates to compounds of the formula I in which the variables are as defined in the specification, to pharmaceutical compositions containing them and to their use for therapeutically lowering blood glucose levels.

Abstract: The present invention describes a process for the preparation of ethyldimethylamine and triethylamine with the following steps: (i) reaction of a mixture of diethylamine and dimethylamine with ethylene in the presence of a catalyst from the group of alkali metal dimethylamides, alkali metal diethylamides and alkali metal hydrides (ii) removal of the catalyst (iii) distillation separation of the resulting mixture in triethylamine and ethyldimethylamine and optionally diethylamine and dimethylamine (iv) optional return of the catalyst and of the starting amines to the reaction. The process according to the invention permits the coproduction of ethyldimethylamine and diethylamine in a simple process.